Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael R Harrison

Showing results (151-160 of 183) with videos related to

Pageof 19
Sort By:
Clinical Genitourinary Cancer|June 3, 2020
PD-L1 Assay Concordance in Metastatic Renal Cell Carcinoma and Metastatic Urothelial CarcinomaLandon C Brown, Jason Zhu, Matthew K Labriola, et al.
Prostate Cancer and Prostatic Diseases|March 16, 2022
A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancerLandon C Brown, Susan Halabi, Jason A Somarelli, et al.
Cancer Chemotherapy and Pharmacology|January 15, 2013
A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancerEmmanuel S Antonarakis, Elisabeth I Heath, Edwin M Posadas, et al.
European Urology Oncology|February 18, 2020
Phase II Trial of Enzalutamide and Androgen Deprivation Therapy with Salvage Radiation in Men with High-risk Prostate-specific Antigen Recurrent Prostate Cancer: The STREAM TrialRhonda L Bitting, Patrick Healy, Daniel J George, et al.
Journal for Immunotherapy of Cancer|March 3, 2021
<i>LRP1B</i> mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer typesLandon C Brown, Matthew D Tucker, Ramy Sedhom, et al.
European Urology|December 13, 2023
Spatial Relationships in the Tumor Microenvironment Demonstrate Association with Pathologic Response to Neoadjuvant Chemoimmunotherapy in Muscle-invasive Bladder CancerWolfgang Beckabir, Sara E Wobker, Jeffrey S Damrauer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2014
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II TrialRobert J Motzer, Brian I Rini, David F McDermott, et al.
Prostate Cancer and Prostatic Diseases|March 11, 2022
A randomized controlled trial comparing changes in fitness with or without supervised exercise in patients initiated on enzalutamide and androgen deprivation therapy for non-metastatic castration-sensitive prostate cancer (EXTEND)Michael R Harrison, Paul G Davis, Michel G Khouri, et al.
Biomarker Research|November 4, 2021
Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinomaMatthew D Tucker, Landon C Brown, Yu-Wei Chen, et al.
Journal for Immunotherapy of Cancer|March 29, 2020
Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter studyNieves Martinez Chanza, Wanling Xie, Majd Issa, et al.
Pageof 19

Showing results (151-160 of 183) with videos related to

Sort By:
Pageof 19
Clinical Genitourinary Cancer|June 3, 2020
PD-L1 Assay Concordance in Metastatic Renal Cell Carcinoma and Metastatic Urothelial CarcinomaLandon C Brown, Jason Zhu, Matthew K Labriola, et al.
Prostate Cancer and Prostatic Diseases|March 16, 2022
A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancerLandon C Brown, Susan Halabi, Jason A Somarelli, et al.
Cancer Chemotherapy and Pharmacology|January 15, 2013
A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancerEmmanuel S Antonarakis, Elisabeth I Heath, Edwin M Posadas, et al.
European Urology Oncology|February 18, 2020
Phase II Trial of Enzalutamide and Androgen Deprivation Therapy with Salvage Radiation in Men with High-risk Prostate-specific Antigen Recurrent Prostate Cancer: The STREAM TrialRhonda L Bitting, Patrick Healy, Daniel J George, et al.
Journal for Immunotherapy of Cancer|March 3, 2021
<i>LRP1B</i> mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer typesLandon C Brown, Matthew D Tucker, Ramy Sedhom, et al.
European Urology|December 13, 2023
Spatial Relationships in the Tumor Microenvironment Demonstrate Association with Pathologic Response to Neoadjuvant Chemoimmunotherapy in Muscle-invasive Bladder CancerWolfgang Beckabir, Sara E Wobker, Jeffrey S Damrauer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2014
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II TrialRobert J Motzer, Brian I Rini, David F McDermott, et al.
Prostate Cancer and Prostatic Diseases|March 11, 2022
A randomized controlled trial comparing changes in fitness with or without supervised exercise in patients initiated on enzalutamide and androgen deprivation therapy for non-metastatic castration-sensitive prostate cancer (EXTEND)Michael R Harrison, Paul G Davis, Michel G Khouri, et al.
Biomarker Research|November 4, 2021
Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinomaMatthew D Tucker, Landon C Brown, Yu-Wei Chen, et al.
Journal for Immunotherapy of Cancer|March 29, 2020
Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter studyNieves Martinez Chanza, Wanling Xie, Majd Issa, et al.
Pageof 19